
REFERENCES
==========
[0] N/A. Lyst M. J., Bird A. Rett syndrome: a complex disorder with simple roots. Nature Reviews Genetics (2015)
[1] 21632916. Samaco R. C., Neul J. L.. Complexities of Rett Syndrome and MeCP2. The Journal of Neuroscience (2011)
[2] 17988628. Chahrour M, Zoghbi H. Y.. The story of Rett syndrome: from clinic to neurobiology. Neuron (2007)
[3] 32139519. Sjöstedt E, et al.. An atlas of the protein-coding genes in the human, pig, and mouse brain. Science (2020)
[4] 34321199. Karlsson M, et al.. A single–cell type transcriptomics map of human tissues. Science Advances (2021)
[5] 9048985. Lappalainen R., Liewendahl K., Sainio K., Nikkinen P, Riikonen R. S.. Brain perfusion SPECT and EEG findings in Rett syndrome. Acta Neurologica Scandinavica (1997)
[6] 23481597. Bianciardi G, et al.. Microvascular abnormalities in Rett syndrome. Clin Hemorheol Microcirc (2013)
[7] 29251840. Saili K. S., et al.. Blood-brain barrier development: Systems modeling and predictive toxicology. Birth Defects Res (2017)
[8] 20944625. Daneman R., Zhou L., Kebede A. A., Barres B. A.. Pericytes are required for blood–brain barrier integrity during embryogenesis. Nature (2010)
[9] 22198708. Ek C. J., Dziegielewska K. M., Habgood M. D., Saunders N. R.. Barriers in the developing brain and Neurotoxicology. Neurotoxicology (2012)
[10] 19741632. Saunders N. R., Joakim Ek C, Dziegielewska K. M.. The neonatal blood-brain barrier is functionally effective, and immaturity does not explain differential targeting of AAV9. Nat Biotechnol (2009)
[11] 24309662. Obermeier B., Daneman R, Ransohoff R. M.. Development, maintenance and disruption of the blood-brain barrier. Nat Med (2013)
[12] 27452664. Aschner M, et al.. Reference compounds for alternative test methods to indicate developmental neurotoxicity (DNT) potential of chemicals: example lists and criteria for their selection and use. Altex (2017)
[13] 25605028. Bal-Price A, et al.. Putative adverse outcome pathways relevant to neurotoxicity. Crit Rev Toxicol (2015)
[14] 20627076. Corada M, et al.. The Wnt/beta-catenin pathway modulates vascular remodeling and specification by upregulating Dll4/Notch signaling. Dev Cell (2010)
[15] 16177780. Weis S. M., Cheresh D. A.. Pathophysiological consequences of VEGF-induced vascular permeability. Nature (2005)
[16] 22048062. Zlokovic B. V.. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nature Reviews Neuroscience (2011)
[17] 29377008. Sweeney M. D., Sagare A. P., Zlokovic B. V.. Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nature Reviews Neurology (2018)
[18] 25757748. Gray M. T., Woulfe J. M.. Striatal Blood–Brain Barrier Permeability in Parkinson’S Disease. Journal of Cerebral Blood Flow & Metabolism (2015)
[19] 23637226. Shaltiel-Karyo R, et al.. A Blood-Brain Barrier (BBB) Disrupter Is Also a Potent α-Synuclein (α-syn) Aggregation Inhibitor: A NOVEL DUAL MECHANISM OF MANNITOL FOR THE TREATMENT OF PARKINSON DISEASE (PD) *. Journal of Biological Chemistry (2013)
[20] 37009464. Lee R. L., Funk K. E.. Imaging blood-brain barrier disruption in neuroinflammation and Alzheimer’s disease. Front Aging Neurosci (2023)
[21] 37189354. Pepe G. Blood–Brain Barrier Integrity Is Perturbed in a Mecp2-Null Mouse Model of Rett Syndrome. Biomolecules (2023)
[22] 23705018. Panighini A, et al.. Vascular Dysfunction in a Mouse Model of Rett Syndrome and Effects of Curcumin Treatment. PLOS ONE (2013)
[23] 29090078. Pacheco N. L., et al.. RNA sequencing and proteomics approaches reveal novel deficits in the cortex of Mecp2-deficient mice, a model for Rett syndrome. Molecular Autism (2017)
[24] 23770565. Lyst M. J., et al.. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat Neurosci (2013)
[25] N/A. Luo A. C., et al.. A streamlined method to generate endothelial cells from human pluripotent stem cells via transient doxycycline-inducible ETV2 activation. Angiogenesis (2024)
[26] 32908310. Palikuqi B, et al.. Adaptable haemodynamic endothelial cells for organogenesis and tumorigenesis. Nature (2020)
[27] 28413025. Cui N., Hu M, Khalil R. A.. Biochemical and Biological Attributes of Matrix Metalloproteinases. Prog Mol Biol Transl Sci (2017)
[28] 25790865. Issler O, Chen A. Determining the role of microRNAs in psychiatric disorders. Nature Reviews Neuroscience (2015)
[29] 20368621. Szulwach K. E., et al.. Cross talk between microRNA and epigenetic regulation in adult neurogenesis. Journal of Cell Biology (2010)
[30] 20716963. Urdinguio R. G., et al.. Disrupted microRNA expression caused by Mecp2 loss in a mouse model of Rett syndrome. Epigenetics (2010)
[31] 26344767. Tsujimura K, et al.. miR-199a Links MeCP2 with mTOR Signaling and Its Dysregulation Leads to Rett Syndrome Phenotypes. Cell Reports (2015)
[32] 19120690. van Solingen C, et al.. Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. J Cell Mol Med (2009)
[33] 30670076. Liu W, Wang X. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biology (2019)
[34] 28529319. Saharinen P., Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin–TIE pathway. Nature Reviews Drug Discovery (2017)
[35] 19234476. Augustin H. G., Young Koh G., Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system. Nature Reviews Molecular Cell Biology (2009)
[36] 35370273. Zhang H., Yamaguchi T., Kokubu Y, Kawabata K. Transient ETV2 Expression Promotes the Generation of Mature Endothelial Cells from Human Pluripotent Stem Cells. Biological and Pharmaceutical Bulletin (2022)
[37] N/A. Wang K, et al.. Robust differentiation of human pluripotent stem cells into endothelial cells via temporal modulation of ETV2 with modified mRNA. Science Advances ()
[38] 30032046. Campisi M, et al.. 3D self-organized microvascular model of the human blood-brain barrier with endothelial cells, pericytes and astrocytes. Biomaterials (2018)
[39] 29581463. Osaki T., Sivathanu V, Kamm R. D.. Engineered 3D vascular and neuronal networks in a microfluidic platform. Scientific Reports (2018)
[40] 31112823. Offeddu G. S., et al.. An on-chip model of protein paracellular and transcellular permeability in the microcirculation. Biomaterials (2019)
[41] 34997242. Hajal C, et al.. Engineered human blood–brain barrier microfluidic model for vascular permeability analyses. Nature protocols (2022)
[42] 12540195. Van den Steen P. E., et al.. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol (2002)
[43] 12730128. Visse R, Nagase H. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases. Circulation Research (2003)
[44] 19631700. Fanjul-Fernández M., Folgueras A. R., Cabrera S, López-Otín C. Matrix metalloproteinases: Evolution, gene regulation and functional analysis in mouse models. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2010)
[45] 18694565. Wang S, et al.. The Endothelial-Specific MicroRNA miR-126 Governs Vascular Integrity and Angiogenesis. Developmental Cell (2008)
[46] N/A. Wang L, et al.. Sensing and guiding cell-state transitions by using genetically encoded endoribonuclease-mediated microRNA sensors. Nature Biomedical Engineering (2024)
[47] N/A. Qu M.-J., et al.. MicroRNA-126 is a prospective target for vascular disease. Neuroimmunology and Neuroinflammation (2018)
[48] 15372072. Lee Y, et al.. MicroRNA genes are transcribed by RNA polymerase II. Embo j (2004)
[49] N/A. Liu Y, et al.. MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons. Neuron (2024)
[50] 24636259. Cheng T.-L., et al.. MeCP2 Suppresses Nuclear MicroRNA Processing and Dendritic Growth by Regulating the DGCR8/Drosha Complex. Developmental Cell (2014)
[51] 34010654. Nakashima H, et al.. MeCP2 controls neural stem cell fate specification through miR-199a-mediated inhibition of BMP-Smad signaling. Cell Reports (2021)
[52] 28117381. Di Pardo A, et al.. Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease. Sci Rep (2017)
[53] N/A. Barisano G, et al.. Blood–brain barrier link to human cognitive impairment and Alzheimer’s disease. Nature Cardiovascular Research (2022)
[54] N/A. Aragón-González A., Shaw P. J., Ferraiuolo L. Blood-Brain Barrier Disruption and Its Involvement in Neurodevelopmental and Neurodegenerative Disorders. Int J Mol Sci (2022)
[55] 32979312. Pulido R. S., et al.. Neuronal Activity Regulates Blood-Brain Barrier Efflux Transport through Endothelial Circadian Genes. Neuron (2020)
[56] 38343438. Gan Y, et al.. Gut microbes in central nervous system development and related disorders. Front Immunol (2023)
[57] 26267216. Agarwal V., Bell G. W., Nam J.-W., Bartel D. P.. Predicting effective microRNA target sites in mammalian mRNAs. eLife (2015)